TN2013000115A1 - Pharmaceutical combinations - Google Patents
Pharmaceutical combinationsInfo
- Publication number
- TN2013000115A1 TN2013000115A1 TNP2013000115A TN2013000115A TN2013000115A1 TN 2013000115 A1 TN2013000115 A1 TN 2013000115A1 TN P2013000115 A TNP2013000115 A TN P2013000115A TN 2013000115 A TN2013000115 A TN 2013000115A TN 2013000115 A1 TN2013000115 A1 TN 2013000115A1
- Authority
- TN
- Tunisia
- Prior art keywords
- combination
- mtor
- treatment
- simultaneous
- separate
- Prior art date
Links
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002062 proliferating effect Effects 0.000 abstract 3
- 230000003197 catalytic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 2
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical combination which comprises (a) an mTOR catalytic inhibitor, such as a catalytic phosphatidylinositol- 3-kinase (PI3K) and mTOR inhibitor compound which is an imidazoquinoline derivative and (b) at least one allosteric mTOR inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of an mammalian target of rapamycin (mTOR) kinase dependent proliferative diseases; and the uses of such a combination in the treatment of mTOR kinase dependent proliferative diseases; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/054536 WO2012047775A1 (en) | 2010-10-04 | 2011-10-03 | Pharmaceutical combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000115A1 true TN2013000115A1 (en) | 2014-06-25 |
Family
ID=54360795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000115A TN2013000115A1 (en) | 2011-10-03 | 2013-03-18 | Pharmaceutical combinations |
Country Status (1)
| Country | Link |
|---|---|
| TN (1) | TN2013000115A1 (en) |
-
2013
- 2013-03-18 TN TNP2013000115A patent/TN2013000115A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500581A1 (en) | Pharmaceutical combinations | |
| MX2009008486A (en) | Imidazoquinolines as dual lipid kinase and mtor inhibitors. | |
| PH12012502161A1 (en) | Pharmaceutical formulations comprising pioglitazone and linagliptin | |
| MX2013012588A (en) | Kinase inhibitors. | |
| IL231226A (en) | Compounds and compositions as c-kit kinase inhibitors, pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating diseases | |
| AU2016219653A1 (en) | Crystallization Method and Bioavailability | |
| WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| GB201118656D0 (en) | New compounds | |
| WO2013052699A3 (en) | Novel quinoxaline inhibitors of pi3k | |
| MX349004B (en) | New compounds. | |
| BR112014018910A8 (en) | PHARMACEUTICAL PRODUCT, KIT, USE OF VEMURAFENIB, PRODUCTS, METHODS, COMPOSITIONS AND INNOVATIVE USES | |
| TN2013000392A1 (en) | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor | |
| UA106634C2 (en) | Solid pharmaceutical dosage form | |
| MY189427A (en) | Pyrazolyl quinoxaline kinase inhibitors | |
| WO2011086531A3 (en) | New anti-malarial agents | |
| WO2011157416A3 (en) | Transdermal administration of memantine | |
| PH12014500809A1 (en) | Polymorphs of arry-380, a slective herb2 inhibitor and pharmaceutical compositions containing them | |
| NZ703940A (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| CR20110338A (en) | LOW CONCENTRATION IMIQUIMOD FORMULATIONS AND SHORT-TERM DOSE REGIMES TO TREAT ACTINIC KERATOSIS | |
| AR085183A1 (en) | COMPOUND 6- (1-METHYL-1H-PIRAZOL-4-IL) -3- (2-METHYL-2H-INDAZOL-5-ILTIO) - [1,2,4] TRIAZOL [4,3-B] PIRIDAZINE, PHARMACEUTICAL COMPOSITION THAT UNDERSTAND AND USE IT TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT CANCER | |
| MX369518B (en) | Combination of pi3k inhibitor and c-met inhibitor. | |
| MX2012013879A (en) | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases. | |
| IN2014DN01619A (en) | ||
| AU2018256668A1 (en) | Combination therapy comprising an inhibitor of JAK, CDK and PIM |